Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

BACKGROUND Passive immunotherapy with convalescent plasma (CP) is a potential
treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …

Objective: Coronavirus disease 2019 is a heterogeneous disease most frequently causing
respiratory tract infection, which can induce respiratory failure and multiple organ …

BACKGROUND COVID-19 convalescent plasma (CCP) has been considered a treatment
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing …

Importance Convalescent plasma (CP) has been generally unsuccessful in preventing
worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

A single center open label phase 2 randomised control trial (Clinical Trial Registry of India
No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of …